Introduction
Glioblastoma multiforme (GBM) is the most lethal and most frequent type of astrocytic brain tumor in adults. 1 It is a malignant, highly recurrent intracranial neoplasm with a rapidly progressive and fatal outcome. Patients who undergo the maximum tumor resection that is safely possible and standard radiochemotherapy with temozolomide (TMZ) only achieve a median survival time of only 14.6 months, and the 5-year survival rate of patients is less than 10%. 2 Glioma-associated seizures (GAS) frequently occur among glioma patients. Approximately 30%-50% of GBM patients will experience seizure activity before surgery, and 6%-45% experience seizures post-diagnosis. 3 However, it has been reported that GBM patients with a history of seizures will have a better prognosis than patients without seizures, which raises questions about whether the antiepileptic drugs, especially those with antitumor functions, play a role in this process. Valproic acid (VPA) has evolved beyond its original use in the 1960s, as an established anticonvulsant drug and mood stabilizer, into an anticancer drug. 4 Preclinical studies within the last decade have suggested that VPA and its analogs could affect tumor cells in many respects, such as inhibition of a subset of histone deacetylases (HDAC) and cellular kinases, which could affect gene transcription through histone hyperacetylation, DNA hypomethylation, and modulation of the MAPK signaling pathway. 5 As a consequence, VPA could inhibit tumor angiogenesis and induce differentiation and apoptosis in diverse types of tumor cells. Some clinical studies have reported the outcome of GBM patients with valproic acid for seizure prophylaxis or treatment, and it appears that most, but not all, of these reports have suggested that VPA could prolong overall survival in GBM patients. 6 However, the combination of the results of these studies in our meta-analysis increases the statistical power and may provide sufficient information to show a credible survival benefit of VPA treatment. Therefore, we conducted a survival analysis for valproic acid treatment of adult glioblastoma multiforme. Using meta-analysis, we initiated time-to-event analyses, which are extremely important for malignant tumors such as glioblastoma multiforme. Novel methods in the treatment of this devastating cancer are urgently needed.
Methods

Search strategy
In February 2014, a bibliographic search was performed in the EMBASE, MEDLINE, ClinicalTrials.gov and Cochrane Central Register of Controlled Trials databases to identify potentially relevant articles or conference abstracts that reported the outcome of patients diagnosed with glioblastoma multiforme, and we initiated the survival analysis of patients treated with or without valproic acid. The search was limited to studies written in English. Two investigators (Y.Y and W.X) independently evaluated papers with respect to the inclusion and exclusion criteria, and any controversies were settled by discussion and consensus. The references contained in the identified trials were also examined to identify any other relevant published or unpublished articles. We used combinations of the following search terms: glioma, valproic acid, outcome and brain tumor (details of the search criteria are provided in Supplemental file 1).
Inclusion and exclusion criteria
The inclusion criteria were as follows:
(a) Because drug use may involve ethical issues and limited or no RCTs, all comparative studies (i.e., trial, cohort, case-control and observational studies) of the relevant AEDs were included. (b) The glioma cases were histologically confirmed, and all included patients had undergone surgery or biopsy; the age of all patients was >17 years. (c) The articles provided survival status, hazard ratio (HR), and 95% confidence intervals (CIs) or information sufficient to calculate these variables from the raw data (including distinct KaplanMeier survival curves, number of patients of the research and control team, and follow up time).
We excluded studies for the following reasons:
(i) Either the HR data were not available or other raw data were insufficient to conduct a meta-analysis. (ii) The patients had only received a biopsy or radiochemotherapy. (iii) The article type was a letter, editorial or review.
Data extraction and end points
The first two authors (Y.Y. and W.X) extracted the data from each eligible article with a standardized form. Disagreements were resolved through discussion or consultation with another author (M.Q). Study designs, patient characteristics, operational definitions, combination therapy, patient outcomes, HR, and 95% CIs were extracted from the articles. We also sent emails to the corresponding authors requesting missing information, as appropriate.
Overall survival (OS) is based on death from any cause. Progression-free survival (PFS) is the length of time during and after surgery in which the disease being treated does not get worse. Data for patients alive without progression were censored on the date of last follow-up evaluation.
Statistical analyses
Our primary outcome was the overall survival of the GBM patients. We conducted meta-analyses when data were available from more than one study. Hazard ratio (HR) and 95% confidence intervals presented in the studies were used to estimate the pooled risk. If the HR was not reported in the article, we used the Engauge Digitizer 4.1 (QT) to extract the time-to-event data from KaplanMeier survival curves, and estimated the Hazard ratio (HR) and 95% confidence intervals by the methods recommended by Tierney. 8 The heterogeneities of the studies were assessed using Cochran's Q statistic and the I 2 statistic. When the p value was 0.1 and the I 2 value was >50%, the heterogeneity was considered significant. Publication biases were estimated using Egger's tests, and p values below 0.05 were considered evidence of publication bias. All p values were two-sided. All analyses were performed with STATA version 11 (STATA/SE, College Station, TX). Because the characteristics of eligible patients, study designs, and usage of valproic acid were not consistent across the articles, we performed further subset and sensitivity analyses to explore possible explanations of heterogeneity and to assess the potential effects of these variables on the outcomes. The Newcastle-Ottawa Quality Assessment Scale, which was recommended by the Cochrane Non-Randomized Studies Methods Working Group, was used to assess our included studies. Fig. 1 shows the flow diagram of the electronic literature search and selection of articles. A total of 166 unique publications were identified after the exclusion of duplicates, and the titles or abstracts of these articles were examined to exclude unrelated studies. Ultimately, 53 relevant articles were identified as primary studies, and the full texts of these articles were retrieved. Next, we identified six studies as eligible for our meta-analysis. The authors of these studies were contacted for further information if the data presented in the article was insufficient for our needs, e.g., the paper reported by Me'lanie S. M. van Breemen 8 only provided K-M curves, but did not include numbers of patients and the follow-up time. The meta-analysis was ultimately based on five studies (this information is summarized in Table 1 ). One of the studies was conducted in North America, one was conducted in Asia, and three were conducted in Europe. All studies were published recently (published during 2011-2013). Table 1 displays the design characteristics of the five studies that were included in our meta-analysis. Overall, 1634 patients were included; all patients had been diagnosed with glioblastoma multiforme. The largest cohort study was conducted by M. Weller et al. 15 (2011) and included 587 GBM patients. Among the included studies, 59% of patients received chemotherapy, most of them were treated with temozolomide, and 94.3% of the patients underwent radiotherapy. Phenytoin and levetiracetam were the most commonly used antiepileptic drugs beyond valproic acid used to treat patients. Only two percent of the total patients had missing data ( Table 2) .
Results
Search results and study characteristics
Although most trials provided enough information about medical treatment strategies, e.g., the number of patients that underwent surgery, radiotherapy or chemotherapy, only two studies described the VPA schedule. Melissa Kerkhof 9 reported using VPA as a first-line anticonvulsant instituted at a maintenance dose of 1000-2000 mg. Hong-Chieh Tsai 10 reported using an initial VPA dose of 400 mg q8h, with a target serum concentration of 50-100 mg/mL. The last three trials only provided information about using VPA as an antiepileptic drug and the period of use (Table 3) .
Survival analysis and heterogeneity
Of the five trials, four reported a significantly longer survival of GBM patients who had been treated with VPA after surgery ( Table 1) . Not surprisingly, the meta-analysis confirmed the benefit of treatment with VPA (HR, 0.56; 95% CI, 0.44-0.71). No statistical heterogeneity between trials was found (p = 0.568), I 2 = 0.0% (variation in ES attributable to heterogeneity). We then performed a subset analysis comparing VPA vs. non-VPA use and VPA vs. other AED use; there were four studies included in the analysis. Glioblastoma multiforme patients using VPA showed a relatively better outcome when compared to patients using nonAEDs or other-AEDs. Patients using VPA showed a hazard ratio of 0.74 with a 95% confidence interval of 0.59-0.94 vs. patients using other-AEDs, and a hazard ratio of 0.66 with a 95% confidence interval of 0.52-0.84 vs. patients with no AED treatment. No heterogeneity was found in the subset analysis.
Discussion
A total of 1634 patients with a confirmed glioblastoma multiforme diagnosis were examined in our meta-analysis. Our goal was to provide a relatable, powerful conclusion about whether valproic acid could prolong the survival of adults with GBM and to give guidance for clinical treatment and further study.
Initially, we found distinct evidence of a beneficial effect of adjuvant VPA therapy (HR = 0.56). However, the primary endpoint of survival in the included studies was based on different control groups (non-AED or other AEDs), although no heterogeneity was found in the main meta-analysis. In Fig. 2 , we extracted survival data from the results section in the abstract, and we defined the result reported in the abstract as the primary endpoint that the author wanted to disclose, but the results from Fig. 2 could not be applied to clinical practice because different control groups were used. Then, we conducted the sub-group analysis based on the non-AED and other AEDs groups, which contained more clinical significance. There was obvious evidence that VPA treatment was beneficial and could prolong the life of patients with GBM when compared to patients in the non-AED group (HR = 0.74) and other-AEDs group (HR = 0.66) (Fig. 3) .
Valproic acid (approved in 1997) is a well established nonenzyme inducing antiepileptic drug and is also defined as a second generation anticonvulsant. The reason that VPA use possibly could have prolonged the survival time of GBM patients is still unclear. Patrick Y. Wen 11 suggested that VPA could increase the bioavailability of temozolomide by decreasing its clearance by 5% (www.temodar.com), but the same effect cannot be observed with phenytoin or phenytoin and adjuvant TMZ treatment. Another potential benefit of VPA may be due to its action as a histone deacetylase (HDAC) inhibitor. 12 As a HDAC-inhibiting agent, valproic acid might enhance the sensitivity of tumor cells to chemotherapy, arrest cell growth, induce the differentiation or apoptosis of glioma cells, and improve the survival of patients when combined with one or more chemotherapeutic agents. In addition to our included studies, a previously published study also suggested that VPA could prolong survival. Weller and colleagues Autophagy represents an alternative tumor-suppressing mechanism that overcomes the dramatic resistance of malignant gliomas to radiotherapy and proapoptotic-related chemotherapy. 13 After years of clinical practice, VPA has proved to be well tolerated and safe over a wide range of plasma levels. Sedation, dizziness and tremor are common neurological side effects. 14 Other complications, such as hyperammonemia or hematological toxicity, may occur relatively frequently, but most patients are mainly asymptomatic.
The results of our analysis should be interpreted with caution, especially because no revolutionary drugs have been discovered in recent years for newly diagnosed GBM patients since temozolomide was adopted into clinical practice. Obviously, it would be of great value to explore the use of valproic acid as a standard treatment, such as surgery and chemoradiotherapy, in GBM. However, before VPA can be written into guidelines, several randomized comparative multicenter clinical studies should be conducted. At the date of this manuscript, there have been no related RCTs published in any journal. However, two phase II trials, which are registered in clinicaltrials.gov (NCT00302159 and NCT00879437), are underway (see Table 1 ). We anxiously await the results of these international RCTs and hope that the results of these studies will enhance the treatment of glioblastoma.
Abundant preclinical in vivo and in vitro research has suggested that VPA can regulate tumor cells in many respects (summarized in Fig. 4) . The most important effect of VPA is the inhabitation of the HDAC, which subsequently modulates the MAPK signaling pathway, 16 the b-catenin pathway (associated with metastatic growth of tumor cells) 17 and other further pathways. 18, 19 Thelen P
showed that VPA could particularly induce apoptosis of the cancer cell line LNCaP. 20 It has also been proven that VPA application to tumor cells can not only generate a decrease of vascular endothelial growth factor (VEGF) but also lead to down-regulation of its coding mRNA, which is highly relevant for the treatment of malignant solid tumors with high neovascularization, such as glioblastoma multiforme. 21 Even though the results from our meta-analysis seem promising, there were some limitations. Most of the results discussed were generated through unplanned retrospective analyses. The selection of the AEDs that were used depended on the investigators' preferences and local practices, although we did not find evidence of a bias. However, beyond this limitation, retrospective studies can be used as a joint analysis to guide us in deciding the next step of whether to conduct a large-scale RCT investigating the impact of co-medication with valproic acid in GBM patients. Progression-free survival (PFS) is another important index for malignant tumors. However, we evaluated overall survival (OS) because we could not combine the hazard ratio (HR) of our selected studies because only one trial reported the PFS. No significant difference in outcome was observed for PFS in the study of M. Weller.
15
Based on previously mentioned promising results from clinical and preclinical studies, should neurosurgeons treating glioblastoma patients routinely prescribe VPA as a standard of care? The answer should be interpreted with caution. However, although all of the included studies are retrospective and may induce unplanned bias, they at least provide us with a significant result that can be used as guide to move forward to conduct a RCT. A randomized phase II trial of valproic acid in newly diagnosed glioblastoma patients should be undertaken.
Conclusions
The results of our study suggest that VPA administration to glioblastoma patients may prolong survival time. Sub-analysis confirmed the benefit of VPA use when compared to groups of patients who received non-AEDs and other-AEDs. Further RCTs exploring the benefits of VPA treatment should be performed.
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